Financial Report

Statement of financial position of PolyPeptide Group AG

As at 31 December

Assets, kCHF

Notes

2021

 

 

 

Current assets

 

 

Cash and cash equivalents

1

117,468

Other receivables from related parties

 

430

Other receivables from group companies

 

3,770

Accrued income and prepaid expenses

 

949

Total current assets

 

122,617

 

 

 

Non-current assets

 

 

Receivables from related parties

 

625

Receivables from group companies

 

66,027

Financial assets

3

2,736

Investments

2

1,919,700

Tangible assets

 

89

Total non-current assets

 

1,989,177

 

 

 

Total assets

 

2,111,794

Liabilities, kCHF

Notes

2021

 

 

 

Current liabilities

 

 

Other liabilities due to third parties

 

580

Other liabilities due to related parties

 

8

Accrued expenses and deferred income

 

205

Total short-term liabilities

 

793

 

 

 

Non-current liabilities

 

 

Liabilities due to group companies

 

1,910

Total long-term liabilities

 

1,910

 

 

 

Shareholders' equity

 

 

Share capital

4

331

Statutory capital reserves

 

 

Reserves from capital contribution

5

2,114,719

Other capital reserves

 

4,949

Accumulated losses

 

 

Net loss brought forward

 

0

Net loss for the period

 

-9,604

Treasury shares

6

-1,304

Total shareholders' equity

 

2,109,091

 

 

 

Total liabilities and shareholders' equity

 

2,111,794